Acadia Healthcare enters the first week of June with a rare convergence: a major same-day analyst upgrade and a short position that, despite a sharp weekly pullback, remains near multi-month highs. The tension between a freshly bullish Street and a still-crowded bear camp defines the stock right now.
The catalyst landing this morning is the Jefferies upgrade from Hold to Buy, with a new $30 target versus the prior $24.50 — a 22% lift. This matters partly because of its timing. The upgrade follows a month in which Jefferies itself built a new institutional stake in the stock, and it arrives just as ACHC has clawed back to $24.42, up 4.8% on the day and 4.0% on the week after a brutal 12% slide over the past month. Jefferies is not alone in moving. Ahead of last month's earnings, RBC Capital and Guggenheim both raised targets to $31, and UBS reiterated Buy with a $31 target in April. The Street consensus has hardened into a buy, with seven buy ratings against five holds and a mean target of $28.86 — representing roughly 18% upside from current levels.
The short side tells a more complicated story. Nearly 24% of the free float remains borrowed — by the ORTEX daily estimate, about 21.8 million shares short. That number has pulled back around 9% over the past week after peaking near 25 million shares in mid-to-late May, but it has risen about 4% over the trailing month, meaning the weekly unwind is a partial reversal rather than a decisive cover. The official FINRA fortnightly reading as of mid-May put days to cover at 8.2 — a figure that underlines just how concentrated the short book remains relative to average trading volume. Bears are not abandoning the thesis; they are trimming at the margin.
Borrow conditions give shorts no particular reason to rush. Cost to borrow has eased 17% on the week to just 0.57% APR — essentially free money to maintain a position. Availability is ample at 262%, meaning roughly two-and-a-half shares are available to lend for every one already borrowed. That wide cushion has actually expanded 33% on the week, loosening the borrow market further. Options positioning is similarly unalarming: the put/call ratio at 0.43 is slightly above its 20-day mean of 0.42, with a z-score near zero. Neither the borrow market nor the derivatives market is flashing squeeze pressure.
The bear case rests on identifiable fundamentals. Government reimbursement risk, ongoing payor denials, and a pattern of facility-level reorganisation all weigh on the revenue line. On the last two earnings prints, ACHC fell more than 6% on the day and over 8% in the following week — a consistent pattern of disappointing post-result reactions. EPS surprise ranks in just the 15th percentile, which fits: the company has a habit of missing or barely meeting consensus. The short score from ORTEX holds near 69, a level it has traded around for the past two weeks without meaningful deterioration or improvement. Quality factor scores remain weak at roughly the 38th percentile, with thin ROCE and negative free cashflow-to-assets dragging against an otherwise reasonable value profile — the EV/EBITDA trades around 8x and the P/E near 15x, both undemanding for a healthcare operator if the earnings line can stabilise.
Institutional ownership data offers one more angle worth noting. Khrom Capital trimmed its stake by nearly 1.9 million shares in Q1, making it the largest known institutional reduction in the period. Meanwhile Morgan Stanley added 2.6 million shares and Citadel built a new 1.4 million-share position in the same quarter. The ownership picture is actively contested, not one-directional.
The next scheduled earnings event falls on 30 July. Between now and then, the key question is whether the Jefferies upgrade — and the broader cluster of May target raises — translates into enough institutional buying to chip away at a short book that has proven resilient even as the stock has bounced. With borrow cheap and availability loose, shorts face little mechanical pressure to cover before that print.
See the live data behind this article on ORTEX.
Open ACHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
